


CV Template of KATRD International Conference 2020

Name	Neil Barnes	
Country	United Kingdom	
Organization	GSK and Bart's NHS Trust	
Current Position	Global Clinical Science Lead, Consultant Physician,	

Educational Background

University: Trinity Hall, Cambridge to read Natural sciences.
Degree: Natural Sciences Tripos BA Hons. June 1976
M.A. Cantab. March 1980

Medical School: Westminster Medical School, October 1976-June 1979
LRCP, MRCS, April 1979
Pre-registration, April 1979
MB, BS, London, June 1979
Full registration, August 1980

POST GRADUATE QUALIFICATIONS; MRCP (UK), March 1981
FRCP, 1995

Professional Experiences

01.09.2019 present	Clinical Science Lead, Respiratory Therapy Area, GSK Honorary Consultant Barts Health NHS Trust, Prof. Respiratory Medicine, Barts and London School of Medicine and Dentistry
01.03.2019- 31.08.2019	Global Medical Expert, Respiratory Therapy Area, GSK Honorary Consultant Barts Health NHS Trust, Prof. Respiratory Medicine, Barts and London School of Medicine and Dentistry
01.10.2013 – 28.02.2019	Medical Head, Global Respiratory Franchise, GlaxoSmithKline. Honorary Consultant Barts Health NHS Trust, Prof. Respiratory Medicine, Barts and the London School of Medicine and Dentistry
30.09.2002 – 30.09.2013	Consultant Respiratory & General Medicine Physician, Royal London Hospitals Trust Professor of Respiratory Medicine, Barts and the London School of Medicine and Dentistry
1/10/1985 – 30.09.2002	Honorary Senior Lecturer, Barts & The London School of Medicine & Dentistry
1.11.88 – 31.03.97	Consultant Respiratory & General Medicine Physician, London Chest Hospital and Royal London Hospital Trust Honorary Senior Lecturer, National Heart and Lung Institute.
19.1.87 – 31.10.88	Senior Registrar in Thoracic Medicine to Dr D Empey, Dr D Geddes, Dr R Rudd, Dr Steel, Dr J Wedzicha, Dr B Mantell. London Chest Hospital

Professional Organizations

Fellow Royal College of Physicians
 British Medical Association
 British Thoracic Society
 Faculty of Pharmaceutical Medicine RCP
 Honorary Fellow Ceylon College of Physicians

Main Scientific Publications

Anti IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane and mild atopic asthmatics

P Flood-Page, A Menzies-Gow, S Phipps, S Ying, A Wangoo, M S Ludwig, N C Barnes, D Robinson, A B Kay
 Journal of Clinical Investigation 2003;112:1029-36

Inspiratory muscle training for asthma

Ram FS., Wellington SR., Barnes NC.
 Cochrane Database S

Variation of CD8+ T Lymphocytes around the bronchial internal perimeter in chronic bronchitis

Gamble E, Burns W, Zhu J, Ansari T, De Rose V, Barnes NC, Jeffry PK
 Eur Respir J, 2003;22(6):995-5

Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity

R Doffinger, M R Helbert, G Barcenas-Morales, K Yang, S Dupuis, L Ceron-Gutierrez, C Espitia-Pinzon, N Barnes, Bothamley, J L Casanova, H J Longhurst, S S Kumararatne
 Clinical Infectious Diseases 2004;38:

Specialist nurse intervention to reduce unscheduled asthma care in deprived multiethnic area: the East Lo randomised controlled trial for high risk (ELECTRA)

Griffiths C., Foster G., Barnes N., Eldridge S., Tate H., Begum S., Wiggins M., Dawson C., Livingstone AE., Chaml M., Coats T., Harris R., Feder GS.
 BMJ. 2004 Jan 17;328(7432):144. Epub 2004

Antibiotics for acute exacerbation of chronic obstructive pulmonary disease

Ram FSF, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC.
 Cochrane Library (ISSN 1464-780X)

Anti-inflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease

N C Barnes, Y-S Qiu, I D Pavord, D Parker, P A Davis, J Zhu, M Johnson, N C Thomson and P K Jeffery
 Am J Respir Crit Care Med 2006; 173: 1-8

Cigarette smoking alters bronchial mucosal immunity in asthma

M Tsoumakidou, W Elston, J Zhu, Z Wang, E Gamble, NM Siafakas, N Barnes and PK Jeffrey
 American Journal of Respiratory and Critical Care Medicine 2007;175:919-925.

Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis

Gamble E, Grootendorst DC, Hattotuwa K, O'Shaughnessy T, Ram FS, Qiu Y, Zhu J, Vignola, AM, Kroegel C, Morell F, Pavord ID, Rabe KF, Jeffrey PK, Barnes NC
 European Respiratory Journal, 2007; 30: 467-71

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma

Flood-Page P, Swenson C, Faifwrmann I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC
 Am J Respir Crit Care Med, 2007; 176: 1062-71

Airway inflammation in asthma with high-fixed or low-fixed plus as – needed budesonide/formoterol

I Pavord, P K Jeffrey, Y Qiu, J Zhu, D Parker, A Carlsheimer, Ian Naya, N Barnes
 Journal of Allergy and Clinical Immunology 2009; 129: 1083-1089

Single Maintenance and Reliever Therapy (SMART) of Asthma: A Critical Appraisal

K Chapman, N Barnes, A Greening, P W Jones, S Pedersen
 Thorax 2010; 65: 747-752

An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease

D Lomas, D Lipson, B Miller L Willits, O Keene, H Barnacle, N Barnes, R Tal-Singer
 Journal of Clinical Pharmacology 2012;52:416-24

A Randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in Moderate persistent asthma

N Barnes, I Pavord, A Chuchalin, J Bell, M Hunter, T Lewis, D Parker, L Pearce-Collins, R Pettipher, J Steiner and C M Perkins
 Clinical & Experimental Allergy, 42; 38-48

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

Bateman E, Ferguson G, Barnes N, Gallagher N, Green Y, Henley M, Banerji D
 European Respiratory Journal. 2013; 42: 1484-94

A Randomised trial of Fluticasone Furoate/Vilanterol (50/25 µg; 100/25 µg) on Lung Function in COPD

Kerwin E, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C
 Respiratory Medicine 2013;107:560-569

A Comparison of the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol With Twice-Daily Fluticasone Propionate/ Salmeterol In Moderate-Severe COPD

Agusti A, Teresa L, Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C
 European Respiratory Journal 2014; 43: 763-772

Safety of Tiotropium through the handihaler – why did meta-analyses and database studies appear to give a false alarm?

NC Barnes, P Jones, K Davis
 Thorax 2014; 69: 598-599

Characterisation of an OCS-dependent severe asthma population treated with Mepolizumab

CM Prazma, S Wenzel, NC Barnes, JA Douglas, BF Hartley, H Ortega
 Thorax 2014 doi 10: 1136

Double-blind multi-centre randomised controlled trial of vitamin D3 supplementation in COPD (ViDiCO)

Adrian R Martineau, Wai Yee James, Richard L Hooper, Neil C Barnes, David A Jolliffe, Claire L Greiller et al
 The Lancet December 2014

Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials

S Pascoe, N Locantore, MT Dransfield, NC Barnes, ID Pavord
 Lancet; April 2015

Understanding Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome – ACOS literature review

G Bushnell, K Wurst, S Pasco, N Barnes, K Kelly-Reif
 Respiratory Medicine 2015

Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu)

Adrian R Martineau, Neil C Barnes, David A Jolliffe, Claire L Greiller et al
 Thorax – May 2015

Lung Deflation Effects on Cardiovascular Structure and Function in Hyperinflated COPD: A Randomized Controlled Trial

Bourbertakh Redha ; Dawn Midwinter; Neil Barnes; James, Wai-ye ; John, Leonette ; Richard Follows
Annals of Internal Medicine
Submitted June 2015

Device Errors in COPD and asthma: Systematic literature review and meta-analysis

Henry Chrystyn, Job van der Palen, Mike Thomas, Bruno Delafont, Anadi Mahajan, Raj Sharma, Neil Barnes
Primary Care Respiratory Journal; April 2017

Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort

Rachael L DiSantostefano, David Hinds, Hoa Van Le, Neil C Barnes
Respiratory Medicine – January 2016

Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis

I Pavord, S Lettis, A Anzueto, N Barnes
Lancet, July 2016

Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in Chronic Obstructive Pulmonary Disease. A randomised trial

Marco Contoli; Alessia Pauletti; Maria Rita Rossi; Antonio Spanevello; Paolo Casolari; Andrea Marcellini; Giacomo Forini; Giulia Gnesini; Brunilda Marku; Neil Barnes; Andrea Rizzi; Giacomo Curradi; Gaetano Caramori; Paolo Mor Alberto Papi
European Respiratory Journal; 2017

The distribution of blood eosinophil levels in a Japanese COPD clinical trials database and in the rest of the world

Neil Barnes; Takeo Ishii; Nobuyuki Hizawa; Dawn Midwinter; Mark James; Emma Hilton; Paul Jones
International Journal of COPD, February 2018

Clinically relevant subgroups in COPD and asthma

Alice M Turner, Lilla Tamasi, Florence Schleich, Mehmet Hoxha, Ildiko Horvath, Renaud Louis, Neil Barnes
European Respiratory 2015; 24: 283-298

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids

Salman Siddiqui, Ian Pavord, Neil Barnes, Alessandro Guasconi, Sally Lettis, Steven Pascoe, Stefano Petruz
European Respiratory Journal, February 2018

Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression

P Daley-Yates, N Brealey, S Thomas, D Austin, S Shabbir, T Harrison, D Singh, N Barnes
British Journal of Clinical Pharmacology 2020;